Thermo Fisher's pharma head talks Brammer Bio and future M&A

Thermo Fisher Scientific is jumping into gene therapy. With drugmakers big and small increasingly entering the space, the Waltham, Massachusetts-based corporation announced a $1.7 billion manufacturing buyout of Brammer Bio, a contract manufacturer of viral vectors.